Phio Pharmaceuticals (NASDAQ:PHIO) CEO Robert Bitterman Purchases 25,000 Shares of Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) CEO Robert Bitterman bought 25,000 shares of the business’s stock in a transaction on Monday, November 9th. The stock was purchased at an average cost of $0.82 per share, with a total value of $20,500.00. Following the purchase, the chief executive officer owned 789,871 shares of the company’s stock, valued at $647,694.22. This represents a 3.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phio Pharmaceuticals Stock Down 3.1%

NASDAQ PHIO opened at $0.81 on Wednesday. The company has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $1.08. Phio Pharmaceuticals Corp. has a 12-month low of $0.75 and a 12-month high of $1.88. The firm has a market cap of $9.73 million, a price-to-earnings ratio of -0.67 and a beta of 0.93.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.36). Equities analysts expect that Phio Pharmaceuticals Corp. will post -1.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.